The treatment of acute myelogenous leukemia has evolved in recent years due to advances in supportive care, the identification of prognostic factors, and the careful evaluation of chemotherapeutic modalities in randomized clinical trials.
Methods
The classification and prognostic features are reviewed, and the results from clinical trials have been evaluated with an emphasis on randomized trials and on both remission induction and postremission phases of management.
Results
The combination of an anthracycline and standard-dose Ara-C form the basis of remission induction. High-dose Ara-C has greater toxicity. For postremission therapy, high-dose Ara-C improves results in those with good risk features or normal cytogenetics. Acute promyelocytic leukemia management includes all-trans-retinoic acid.
Conclusions
Once a patient relapses from a nontransplant approach, high-dose therapy and allogeneic marrow transplantation are considered. Autologous stem cell transplantation cures some patients who do not have a donor.
Get full access to this article
View all access options for this article.
References
1.
RiesL.A., MillerB.A., HankeyB.F., eds. SEER Cancer Statistics Review, 1973–1991: Tables and Graphs.Bethesda, Md: National Cancer Institute, NIH Publ No 94–2789; 1994.
2.
HoW.G., WinstonD.J.Infection and transfusion therapy in acute leukaemia. Clin Haematol.1986; 15: 873–904.
3.
BennettJ.M., CatovskyD., DanielM.T.Proposed revised criteria for the classification of acute myelogenous leukemia: a report of the French-American British Cooperative Group. Ann Intern Med.1985; 103: 620–625.
4.
JanvierM., TobelemG., DanielM.T.Acute monoblastic leukemia: clinical, biological data and survival in 45 cases. Scand J Haematol.1984; 32: 385–390.
5.
VendittiA., Del PoetaG., BuccisanoF.Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood.1997; 89: 621–629.
6.
OlopadeO.I., ThangaveluM., LarsonR.A.Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood.1992; 80: 2873–2882.
7.
WangJ.C., BeauregardP., SoamboonsrupP.Monoclonal antibodies in the management of acute leukemia. Am J Hematol.1995; 50: 188–199.
8.
LeithC.P., KopeckyK.J., GodwinJ.Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study. Blood.1997; 89: 3323–3329.
9.
BallE.D., DavisR.B., GriffinJ.D.Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood.1991; 77: 2242–2250.
10.
ReadingC.L., EsteyE.H., HuhY.O.Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood.1993; 81: 3083–3090.
11.
SchifferC.A., LeeE.J., TomiyasuT.Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood.1989; 73: 263–270.
12.
MrozekK., HeinonenK., de la ChapelleA.Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol.1997; 24: 17–31.
13.
SchochC., HaaseD., HaferlachT.Secondary chromosome aberrations in acute myeloid leukemia with t(8;21)(q22;q22), inv(16)(p13q22) or t(15;17) (q22;q21). Blood.1995; 86(suppl 1): 43a. Abstract.
14.
Pedersen-BjergaardJ., PedersenM., RoulstonD.Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood.1995; 86: 3542–3552.
15.
QuesnelB., KantarjianH., BjergaardJ.P.Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol.1993; 11: 2370–2379.
16.
YatesJ., GlidewellO., WiernikP.Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood.1982; 60: 454–462.
17.
PreislerH., DavisR.B., KirshnerJ.Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood.1987; 69: 1441–1449.
18.
BermanE., HellerG., SantorsaJ.Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood.1991; 77: 1666–1674.
19.
BermanE., McBrideM.Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood.1992; 79: 3267–3273.
20.
RustumY.M., PreislerH.D.Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res.1979; 39: 42–49.
21.
BishopJ.F., MatthewsJ.P., YoungG.A.A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood.1996; 87: 1710–1717.
22.
WeickJ.K., KopeckyK.J., AppelbaumF.R.A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood.1996; 88: 2841–2851.
23.
MitusA.J., MillerK.B., SchenkeinD.P.Improved survival for patients with acute myelogenous leukemia. J Clin Oncol.1995; 13: 560–569.
24.
SchifferC.A.Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood.1996; 88: 3675–3685.
CassilethP.A., BeggC.B., BennettJ.M.4 A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood.1984; 63: 843–847.
27.
WolffS.N., HerzigR.H., PhillipsG.L.High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Semin Oncol.1987; 14(2 suppl 1): 12–17.
28.
CassilethP.A., LynchE., HinesJ.D.Varying intensity of postremission therapy in acute myeloid leukemia. Blood.1992; 79: 1924–1930.
29.
MayerR.J., DavisR.B., SchifferC.A.Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med.1994; 331: 896–903.
30.
BloomfieldC.D., LawrenceD., ArthurD.C.Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group Blood.1994: 84(suppl 1): 111a.
31.
CliftR.A., BucknerC.D., ThomasE.D.The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant.1987; 2: 243–258.
32.
CliftR.A., BucknerC.D., AppelbaumF.R.Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood.1990; 76: 1867–1871.
33.
WeidenP.L., FlournoyN., ThomasE.D.Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med.1979; 300: 1068–1073.
34.
KolbH.J., SchattenbergA., GoldmanJ.M.Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation working Party Chronic Leukemia. Blood.1995; 86: 2041–2050.
35.
BiggsJ.C., HorowitzM.M., GaleR.P.Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood.1992; 80: 1090–1093.
36.
FagioliF., BacigalupoA., FrassoniF.Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. Bone Marrow Transplant.1994; 13: 247–252.
37.
MatthewsD.C., AppelbaumF.R., EaryJ.F.131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. Blood.1996; 88: 142a.
38.
ChopraR., GoldstoneA.H., McMillanA.K.Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. J Clin Oncol.1991; 9: 1840–1847.
39.
McMillanA.K., GoldstoneA.H., LinchD.C.High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood.1990; 76: 480–488.
40.
BrennerM.K., RillD.R., MoenR.C.Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet.1993; 341: 85–86.
41.
GorinN.C., AegerterP., AuvertB.Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood.1990; 75: 1606–1614.
42.
SteinA.S., O'DonnellM.R., ChaiA.In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol.1996; 14: 2206–2216.
43.
MillerC.B., RowlingsP.A., JonesR.J.Autotransplants for acute myelogenous leukemia (AML): effect of purging with 4-hydroperoxycyclophosphamide (4HC). Blood.1995; 86: 100a.
44.
FerrantA., DoyenC., DelannoyA.Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Bone Marrow Transplant.1991; 7: 303–309.
45.
KeatingA., RowlingsP.A., HorowitzM.M.Comparison of HLA-identical sibling and autologous bone marrow transplants for acute myelogenous leukemia (AML). Blood.1994; 84: 201a.
46.
ZittounR.A., MandelliF., WillemzeR.Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med.1995; 332: 217–223.
47.
GamberiB., BandiniG., VisaniG.Acute myeloid leukemia from diagnosis to bone marrow transplantation: experience from a single centre. Bone Marrow Transplant.1994; 14: 69–72.
48.
AppelbaumF.R., CliftR.A., BucknerC.D.Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood.1993; 61: 949–953.
49.
AmadoriS., ArceseW., IsacchiG.Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol.1991; 9: 1210–1214.
50.
EsteyE.Treatment of refractory AML. Leukemia.1996, 10: 932–936.
51.
ListA.F.Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia.1996; 10: 937–942.
52.
SzydloR., GoldmanJ.M., KleinJ.P.Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol.1997; 15: 1767–1777.
53.
SmithM.A., McCaffreyR.P., KarpJ.E.The secondary leukemias: challenges and research directions. J Natl Cancer Inst.1996; 88: 407–418.
54.
AndersonJ.E., GooleyT.A., SchochG.Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood.1997; 89: 2578–2585.
55.
WarrellR.Jr, de TheH., WangZ.Y.Acute promyelocytic leukemia. N Engl J Med.1993; 329: 177–189.
56.
TallmanM.S., KwaanH.C.Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood.1992; 79: 543–553.
57.
ChenZ.X., XueY.Q., ZhangR.A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood.1991; 78: 1413–1419.
58.
TallmanM.S.Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. Leukemia.1996; 10(suppl 1): 12–15.
59.
FenauxP., CastaigneS., DombretH.All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood.1992; 80: 2176–2181.
60.
FenauxP., Le DeleyM.C., CastaigneS.Effect of all-trans-retinoic acid in newly diagnosed promyelocytic leukemia: results of a multicenter randomized trial. Blood.1993; 82: 3241–3249.
61.
TallmanM.S., AndersenJ., SchifferC.A.Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated promyelocytic leukemia (APL). Blood.1995; 86: 488a.
62.
FrankelS.R., EardleyA., LauwersG.The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med.1992; 117: 292–296.
